



MEDIPURE HOLDINGS COMMENCES TRADING ON THE CANADIAN SECURITIES EXCHANGE

November 10, 2014 – Vancouver, BC – Medipure Holdings Inc. (“Medipure,” or “the Company”) [CSE:MDH] is pleased to announce that, effective today, the Company’s common shares have commenced trading on the Canadian Securities Exchange under the ticker symbol ‘MDH.’

Medipure’s listing was facilitated by a plan of arrangement that became effective on October 29, 2014. Complete details of this plan of arrangement are available within a press release entitled “Noor Energy Closes a Plan of Arrangement with Medipure Pharmaceuticals Inc. and Medipure Holdings Inc.,” issued on October 29, 2014.

Medipure’s goal is to conduct pioneering research into the development of cannabinoid-based medicines as prescription pharmaceuticals. Medipure intends to adopt a unique approach towards these pharmaceuticals, creating propriety cannabinoid derivatives that contain reduced tetrahydrocannabinol (“THC”) content, are not delivered via inhalation, and are both designed and proven to effectively treat specific ailments. Medipure hopes to have its first derivative product prepared for market entry by the conclusion of 2015.

In pursuit of this goal, Medipure has already begun to assemble an industry-leading team of medical professionals. This team is led by Dr. John Maynard, the Company’s Chief Medical Officer and Chairman of Vancouver Coastal Health Authority’s Medical Advisory Committee. Dr. Maynard will be immediately supported by Nihar Pandey, a Doctor of Biochemistry and research team leads, Rakshit Kodekalra, a Doctor of Agricultural Science, and Andrew Waye, a Doctor of Chemical and Environmental Toxicology. Medipure has also begun the development of its full-service production and research facility in Maple Ridge, British Columbia. The first phase of this development is slated for completion in early 2015, and will house both a research centre and the Company’s initial production capabilities.

Medipure has formally applied to Health Canada for a Production and Research License, and has completed all the requirements for this application as laid out by the Marijuana for Medical Purposes Regulations (“MMPR”). The Company expects to receive a decision regarding the status of its application during the first quarter of 2015. However, should Medipure not succeed

in immediately securing a Producer's License, the Company will nonetheless be fully capable of conducting its research using product purchased from another Licensed Producer.

"We're very pleased to have formally commenced trading upon the Canadian Stock Exchange," stated Boris Weiss, Medipure's Chief Executive Officer. "Access to the public markets will be critical in providing Medipure with the financial flexibility necessary to pursue our goal of revolutionizing cannabinoid-based medicines. I look forward to sharing our progress towards that goal."

About Medipure Holdings Inc.

Medipure is developing an extensive network of strategic partnerships with extensive experience in developing cannabinoids, medicines containing controlled substances, as well as plant-based prescription pharmaceutical products. Medipure will attempt to bring novel prescription medicines to market, providing patients with serious conditions valuable solutions that make a real difference to quality of life. Medipure will also seek to maximize the value of our products through rapid cost-effective product development, addressing market needs, and establishing strategic partnerships.

For more information, please contact:

Nathan Sellyn
Investor Relations
nsellyn@medipurepharma.com

Boris Weiss
Chief Executive Officer
boris@medipurepharma.com

Forward-Looking Statements

Information in this press release that is not current or historical factual information may constitute forward-looking information, including future-oriented financial information and financial outlooks, within the meaning of securities laws. This information is based on certain assumptions regarding expected growth, results of operations, performance, and business prospects and opportunities. Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the companies cannot provide any assurance that it will prove to be correct. These forward-looking statements are made as of the date of this press release and the companies disclaim any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.